Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
BHP Shares Fall as Jansen Potash Project Costs Surge 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
Trump Says Anthropic No Longer Seen as National Security Threat 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
G7 Explores AI Access Deal With U.S. Amid Anthropic Restrictions 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
Google Gemini Co-Lead Noam Shazeer Leaves for OpenAI Amid AI Talent Race 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
MOUNTAIN VIEW, Calif., Jan. 07, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 34th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2016 at 8:30 a.m. PST. The conference will be held at the Westin St. Francis Hotel in San Francisco, CA.
A live audio webcast of the presentation can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. A replay of the webcast will be available on the Company's website for two weeks following the live presentation.
About ChemoCentryx
ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. CCX168, a C5aR inhibitor, is in Phase II development for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). CCX168 appears to be safe, well tolerated and successful in allowing reduction and elimination of high-dose steroids, part of standard of care for AAV patients, without compromising efficacy or safety during a 12-week treatment period. CCX168 is also in Phase II studies for the treatment of atypical hemolytic uremic syndrome (aHUS) and immunoglobulin A nephropathy, or IgA nephropathy (IgAN). CCX872, a CCR2 inhibitor, successfully completed Phase I development and is in development for the treatment of non-resectable pancreatic cancer. CCX140, a distinct CCR2 inhibitor, successfully completed a Phase II clinical trial where it was shown to be safe and well tolerated while demonstrating statistically significant improvement in albuminuria in patients with diabetic nephropathy. Other clinical programs include CCX507, a next generation CCR9 inhibitor, which has successfully completed Phase I development, vercirnon (also known as Traficet-EN or CCX282) a specific CCR9 inhibitor for the treatment of inflammatory bowel disease, and CCX354, a CCR1 inhibitor which successfully completed a Phase II clinical trial for the treatment of rheumatoid arthritis. ChemoCentryx also has several programs in advanced preclinical development.
Source: ChemoCentryx, Inc.
CCXI-G
Contacts: Susan M. Kanaya Senior Vice President, Finance and Chief Financial Officer [email protected] Media: Denise Powell 510.703.9491 [email protected] Investors: Kimberly Minarovich Burns McClellan 212.213.0006 [email protected]
